Myelodysplastic syndrome (MDS) constitute a group of clonal myeloid neoplasms characterized by anaemia or other cytopenias due to ineffective hematopoiesis, abnormal blood, and bone marrow cell morphology, as well as, the risk for clonal evolution and progression to acute myeloid leukaemia (AML).
Some patients have Myelodysplastic Syndrome cells in their bone marrow even after the treatment, and this condition is called refractory MDS. While some patients have a return of MDS cells in the marrow and a decrease in normal blood cells after remission, which is called a relapse. Patients with Myelodysplastic Syndrome collectively have a high symptom burden and are also at risk of death from complications of cytopenias and AML. Refractory Myelodysplastic Syndrome is typically treated with a different treatment than the first therapy used, and relapsed MDS is typically treated with either the same treatment used before or a different standard treatment. No standard exists for the treatment of MDS relapsing after allogeneic stem cell transplantation.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-market
The Myelodysplastic Syndrome market report also covers emerging drugs, current treatment practices, Myelodysplastic Syndrome market size and share of the individual therapies, current and forecasted Myelodysplastic Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Myelodysplastic Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Myelodysplastic Syndrome Market Key Facts
According to population-based registry data (1993–2008) analysis in Japan, the incidence of MDS sharply increased with age, particularly in those over age 70 years. The incidence in 65–69 years was reported to be 3.1 cases/100,000 (men) and 1.1 cases/100,000 (women), in comparison to 85 years in which the rate was 17.7 and 8.9 cases/100,000, respectively
According to DelveInsight’s analysis, males are affected more as compared to females, in the case of Myelodysplastic Syndrome (MDS).
In MDS-RS, a minimum of 15% of the early red blood cells must be ring sideroblast with a mutation in the SF3B1 gene. It can be divided into two categories (MDS-RS-SLD, MDS-RS-MLD) and rarely turns into AML.
Key Benefits of Myelodysplastic Syndrome Market Report
-
Myelodysplastic Syndrome market report provides an in-depth analysis of Myelodysplastic Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Myelodysplastic Syndrome market report will help in developing business strategies by understanding the Myelodysplastic Syndrome Market trends & developments, key players and future market competition that will shape and drive the Myelodysplastic Syndrome market in the upcoming years.
-
The Myelodysplastic Syndrome market report covers Myelodysplastic Syndrome market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Myelodysplastic Syndrome patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Myelodysplastic Syndrome Market
The Myelodysplastic Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Myelodysplastic Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Myelodysplastic Syndrome market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Myelodysplastic Syndrome Epidemiology
The Myelodysplastic Syndrome epidemiology section covers insights about historical and current Myelodysplastic Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted Myelodysplastic Syndrome epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Myelodysplastic Syndrome Drugs Uptake and Key Companies
The Myelodysplastic Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelodysplastic Syndrome market or expected to get launched in the market during the study period. The analysis covers Myelodysplastic Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key companies in the Myelodysplastic Syndrome market include:
Astex Pharmaceuticals
Onconova Therapeutics
Celgene
Aprea Therapeutics
Celyad
And many others.
Myelodysplastic Syndrome Therapies covered:
Guadecitabine (SGI-110)
Rigosertib
APR-246
CYAD-02
CC-90009
And others.
Table of Content
1. Key Insights
2. Executive Summary
3. Myelodysplastic Syndrome Competitive Intelligence Analysis
4. Myelodysplastic Syndrome Market Overview at a Glance
5. Myelodysplastic Syndrome Disease Background and Overview
6. Myelodysplastic Syndrome Patient Journey
7. Myelodysplastic Syndrome Epidemiology and Patient Population
8. Myelodysplastic Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Myelodysplastic Syndrome Unmet Needs
10. Key Endpoints of Myelodysplastic Syndrome Treatment
11. Myelodysplastic Syndrome Marketed Products
12. Myelodysplastic Syndrome Emerging Therapies
13. Myelodysplastic Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Myelodysplastic Syndrome Market Outlook (7 major markets)
16. Myelodysplastic Syndrome Access and Reimbursement Overview
17. KOL Views on the Myelodysplastic Syndrome Market.
18. Myelodysplastic Syndrome Market Drivers
19. Myelodysplastic Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Myelodysplastic Syndrome – Epidemiology Forecast to 2030
DelveInsight’s Myelodysplastic Syndrome – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Myelodysplastic Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Myelodysplastic Syndrome – Pipeline Insights, 2020
Myelodysplastic Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Myelodysplastic Syndrome market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/